Zelluna selected CRO Medpace to manage its first‑in‑human Phase I trial of ZI‑MA4‑1 (ZIMA‑101), an off‑the‑shelf TCR‑NK cell therapy targeting MAGE‑A4 in advanced solid tumors. The scope covers operations, regulatory support, data analysis and pharmacovigilance, with initial clinical data expected by mid‑2026. Zelluna’s allogeneic TCR‑NK approach combines T‑cell receptor targeting of tumor antigen MAGE‑A4 with innate NK‑cell activity to broaden anti‑tumor effect across indications including lung, ovarian, head and neck cancers and sarcomas. The company has engaged UK clinical sites and reported that the first GMP batch has been manufactured and quality‑tested. Zelluna framed the Medpace partnership as a strategic move to leverage experienced early‑phase oncology trial execution as it transitions to the clinic; the results will provide tolerability and early activity readouts critical to the platform’s development.